March 2018

NCI Standard Funding Opportunity Announcements

Current and Recent Program Announcements  |  Current and Recent Requests for Applications
Current and Recent NCI and Trans-NIH Initiatives | Requests for Proposals  |  Standard Due Dates

Updated
Ongoing All Ranks Federal See BAA

Army Research Office (ARO) Broad Agency Announcement (BAA)
for Basic and Applied Scientific Research
for Fiscal Years 2017 through 2022

The purpose of this BAA is to solicit research proposals in the engineering, physical, life, and information sciences for submission to the Army Research Office (ARO) for consideration for possible funding. Whitepapers and proposals will be evaluated only if they are for fundamental scientific study and experimentation directed toward advancing the scientific state of the art or increasing basic knowledge and understanding.  
Due Dates: Open until Mar. 31, 2022
Proposers are to submit white papers prior to submission of a complete proposal. Based on assessment of white papers, feedback will be provided to encourage or discourage submission of full proposals.
Amount & Project Period: No specific dollars have been reserved - 3 years
Eligibility: All Ranks
Contact: Office of Sponsored Research - (x6804)
Link: Funding Opportunities - Open Broad Agency Announcements (BAA)


Open All Ranks Non-federal Clinical Trials

The Gateway for Cancer Research
Research Grants

Gateway focuses on transformational science via effective clinical trials - when basic science translates into human testing and clinical practice.
Due Dates: Rolling requests for funding conducted in two stages: a Letter of Intent (LOI) and if invited, a full application. Applicants must submit via Gateway's Grant Management System
Amount & Project Period: Funding is variable and duration is 1 to 3 years
Eligibility: All Ranks
Contact: Gateway Contacts are: Jerian Dixon-Evans, Research Grants Specialist  Jerian.Dixon-Evans@gatewaycr.org (847) 342-7361 and Domarina Oshana, Ph.D., Director of Research and Grants Domarina.Oshana@gatewaycr.org (847) 342-7443
Link: Grant Application Process

NEW
February 15 (LOI) Postdocs & Junior Faculty Non-federal Myelodysplastic Syndromes

Aplastic Anemia & MDS International Foundation
2018 AAMDS Research Grants

The Foundation is interested in funding research across the spectrum of basic and clinical science, but highest priority is for studies that have the potential to impact prevention, diagnosis, risk-stratification, or treatment of these diseases within three years. Examples include:     
1.  Discovery of biomarkers predicting response or resistance to existing therapies;
2.  Correlative science on patient samples collected from clinical trials, to inform 
     understanding of therapeutic mechanisms;
3.  Late-stage pre-clinical research, with a goal of establishing proof-of-concept for a novel
     therapy;
4.  Basic research that reveals new mechanisms of disease likely to benefit patients.
Due Dates: Feb. 15 (Letter of Intent)
Invited Submissions:  Mar. 28 (OSR) Ι Mar. 30 (Sponsor)
Amount & Project Period: $60,000 - 2 years
Eligibility: Hold an MD or MD/PhD or equiv.;
No nationality restrictions;
Project must represent independent research conducted by applicant;
Preference given to New Investigators who are defined as: post-doctoral fellows, instructors, and those who have been assistant professors for <5 years.
Contact: Office of Sponsored Research (x6804)
Links: RFP | Fund Your Research | proposalCENTRAL
R21 NCI

February 20 All Ranks Federal Clinical/Translational

NCI Clinical and Translational Exploratory/Developmental Studies  (Clinical Trial Optional)  

This FOA supports development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials.
Due Dates: Feb. 16 (OSR) Ι Feb. 20 (Sponsor)
Additional 2018 Due Dates:  June 19 & Oct. 17
Amount & Project Period: $275,000 (Direct Costs) - 2 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-020
















February 20 Postdocs Non-federal Career Development/Immunology

Society for Immunotherapy of Cancer (SITC)
2018 SITC Fellowship Opportunities

These fellowship awards will help support the development of the next generation of immunotherapy experts who have a vested interest in furthering the research and translation of cancer immunotherapy.
Due Dates: Feb. 16 (OSR) Ι Feb. 20 (Sponsor)
Eligibility: Current SITC member;
Hold MD, PhD or combined MD/PhD degree;
Currently hold position as a postdoctoral fellow, resident, research scientist or comparable position;
Be w/in postdoctoral or postgraduate training, or <4 years from completing such training;
Commit 75% effort to research supported by the fellowship
Contact: Office of Sponsored Research (x6804)
Link: 2018 SITC Fellowship Opportunities

SITC-MERCK Cancer Immunotherapy Clinical Fellowship

Amount & Project Period: $100,000 -1 year

SITC-Bristol-Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship

Amount & Project Period: $200,000 - 2 years

SITC-AstraZeneca Postdoctoral Cancer Immunotherapy in Combination Therapies Clinical Fellowship

Amount & Project Period: $100,000 - 1 year
February 21 (LOI) Established Investigators Non-federal Bladder Cancer

Bladder Cancer Advocacy Network (BCAN)
Bladder Cancer Research Innovation Award

Proposed research may be basic, translational, or clinical but must have direct applicability and relevance to bladder cancer and address one of these two questions of interest:
1. What are mechanisms by which the resident microbiota interacts with the biology of urothelial cancer?
2. What are the tumor cell autonomous or microenvironmental determinants of bladder cancer progression to metastasis?
Proposals for innovative projects that will develop preliminary data necessary to prepare and submit a competitive research grant application to a major funding agency are encouraged.
Due Dates: Feb. 21 (Letter of Intent)
Invited Applications: May 14 (OSR) Ι May 16 (Sponsor)
Amount & Project Period: $300,000 - 2 years
Eligibility: Must have a medical and/or doctoral degree;
Must be an independent investigator;
Proof of permanent resident status or a valid work visa is required if applicant is not an American or Canadian citizen;
May not apply both for this award and for a BCAN Young Investigator Award;
Those holding current BCAN Young Investigator Award or Research Innovation Award are not eligible to apply.
Contact: Office of Sponsored Research (x6804)
Link: 2018 Bladder Cancer Research Innovation Award


NEW
February 22 New Faculty Non-federal Career Development

Canadian Institute for Advanced Research
Azrieli Global Scholars Program

This program provides funding, skills training, mentorship, and opportunities to collaborate with outstanding colleagues from diverse disciplines to position scholars as leaders and agents of change within academia and beyond.
Due Dates: Feb. 20 (OSR) Ι Feb. 22 (Sponsor)
Amount & Project Period: $100,000 CDN (Unrestricted) - 2 years
Eligibility: Must hold a PhD (or equiv.);
Must be w/in 5 years of first full-time academic appt. (academic appt. must be no earlier than May 1, 2013);
Postdoctoral fellows are not eligible
Contact: Office of Sponsored Research (x6804)
Links: CIFAR Azrieli Global Scholars Program Detailed Overview


Data Files Available
February 23 All Faculty Ranks Non-federal See Below

National Cancer Database Participant Use Data Files (PUF)

The National Cancer Database (NCDB) sponsored by the American College of Surgeons and the American Cancer Society, is accepting applications for organ-site specific data files for the 2015 PUF release.  This is an open request for cancer data for review and advancement of the quality of care provided to cancer patients through analyses of cases reported to the NCDB.
Due Dates: Feb. 23 (NCDB)
Contact: Questions regarding NCDB PUFs or RFA process for a PUF may be directed to NCDB technical staff at NCDB_PUF@facs.org.
Links: NCDB PUF website
Required Application Elements
Participant Use Data FILE (PUF) Supplemental Documents National Cancer Database (NCDB)

February 26 Postdocs & Junior Faculty Non-federal Career Development/Bladder Cancer

Bladder Cancer Advocacy Network (BCAN)
Young Investigator Award and
Patient-Centered Clinical Research Young Investigator Award

These Awards are intended to support development of outstanding research scientists and clinical cancer research investigators with a commitment to improving understanding and treatment of bladder cancer.  Projects must be bladder cancer specific (including upper tract urothelial carcinoma).
For the Young Investigator Award, investigators may be working in basic, translational, clinical, epidemiologic, bioengineering or any other field, but must be working in a research environment capable of supporting transformational bladder cancer research.
For the Patient-Centered Clinical YIA, investigators must be working in a research environment capable of supporting transformational patient-oriented clinical bladder cancer research (e.g. studies of access to care, quality of care, quality of life, health disparities, and patient-centered outcomes research), and a statement regarding applicability of the research to the patient-prioritized BCAN Patient Survey Network (PSN) research questions is required. 
Due Dates: Feb. 22 (OSR) Ι Feb. 26 (Sponsor)
Amount & Project Period: $50,000 - 1 year
Eligibility: Must be w/in 6 years of completing a professional degree such as MD, PhD, MD-PhD, MPH, or equivalent or clinical training such as residency or fellowship;
May hold title of Senior Postdoc, Instructor, Research Associate, Assistant Professor or equiv.;
At start of grant, applicant cannot hold title of Assoc. Professor;
Proof of permanent resident status or valid work visa is required if applicant is not an American or Canadian citizen.
Contact: Office of Sponsored Research (x6804)
Links: 2018 Young Investigator Award and Award Guidelines
2018 Patient-Centered Clinical Research Young Investigator
Award and Award Guidelines
R03 NCI

February 27 All Ranks Federal Exploratory Research

NCI Small Grants Program for Cancer Research (NCI Omnibus - Clinical Trial Optional)

This FOA supports small research projects on cancer that can be carried out in a short period of time w/limited resources. An R03 grant supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.
Due Dates: Feb. 23 (OSR) Ι Feb. 27 (Sponsor)
Additional 2018 Due Dates:  June 29 & Oct. 26
Amount & Project Period: $50,000/yr. (Direct Costs) - 2 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-021
U54 NCI
February 27 Established Investigators Federal Health Disparities

Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (Clinical Trial Optional)

The CPACHE Program develops and maintains comprehensive, long-term, and mutually beneficial partnerships between institutions serving underserved health disparity populations and underrepresented students (ISUPSs) and NCI-designated Cancer Centers (CCs). The institutions in each partnership are expected to work collaboratively to: 1) increase the cancer research and cancer research education capacity of the ISUPSs; 2) increase the number of students and investigators from underrepresented populations engaged in cancer research; 3) improve the effectiveness of CCs in developing and sustaining research programs focused on cancer health disparities and increase the number of investigators and students conducting cancer health disparities research; and 4) develop and implement cancer-related activities that benefit the surrounding underserved communities.
Due Dates: Dec. 13 (Letter of Intent, not required, not binding)
Feb. 23 (OSR) Ι Feb. 27 (Sponsor)
Additional Due Dates:  January 9, 2019; January 9, 2020
Amount & Project Period: 2 institutions:  Max. $2M/yr. (Direct Costs)
3 institutions:  Max. $2.5M/yr. (Direct Costs)
Applications exceeding limits will not be accepted.
Duration:  Max. 5 years
Eligibility: Each partnership must include both types of institutions: 1) institutions serving underserved health disparity population and underrepresented students (ISUPSs); and 2) NCI-designated Cancer Centers (CCs). (Partnerships involving more than two institutions require NCI approval before submission of an  application.)
PD(s)/PI(s) are preferred to be mid-to-senior-level scientists w/records of obtaining grants. A less experienced investigator at an ISUPS can be designated as one of multiple PDs/PIs, if there is an appropriate institutional investment in this investigator, and a demonstrable collaboration (active or planned) of the less experienced investigator with a more experienced PD/PI.
The contact PD/PI for the CC must be a CC PD/PI.
Both contact PDs/PIs should be reciprocally listed as PD(s)/PI(s) on the linked application from the partner institution.
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-361
R33 NCI

February 28 All Ranks Federal Biospecimen Science

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (Clinical Trial Not Allowed)

This FOA supports further development and validation of emerging technologies improving quality of samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during collection, processing, handling, and/or storage of cancer-relevant biospecimens. For these applications, major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community.
Due Dates: Jan. 30 (Letter of Intent, not required, not binding)
Feb. 26 (OSR) Ι Feb. 28 (Sponsor)
Additional 2018 Due Dates:  May 29 & Sept. 28
Amount & Project Period: $300,000/yr. (Direct Costs) - 3 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
RFA Link: RFA-CA-18-005
Companion RFAs: RFA-CA-18-002, R21 (Clinical Trial Not Allowed)
RFA-CA-18-003, R33 (Clinical Trial Not Allowed)
RFA-CA-18-004, R21 (Clinical Trial Not Allowed)

Foundation-facilitated
February 28 All Ranks Non-federal Cancer Research Projects

Ocala Royal Dames for Cancer Research, Inc.
Cancer Research Funding

This RFP funds medical research into finding cures for cancer.  Applications are sought for research that can be described as translational, pre-clinical - not early bench work.  Proposed projects should be aimed specifically at cancer and have potential for usefulness in the near future.
Due Dates: Feb. 28 (Sponsor Receipt Date)
Amount & Project Period: $50,000 (Total Costs) - 2 years  
Eligibility: All Ranks
Contact: Suzanne Knapp, Moffitt Foundation (x1400)
RFP Link: RFP for Cancer Research Funding
Admin. Supplement NIH
NCI is a participating Institute NEW
March 01 See Below Federal Diversity

Research Supplements to Promote Diversity in Health-Related Research (Clinical Trial Not Allowed)

This FOA informs (PD(s)/PI(s) that funds may available for administrative supplements to improve the diversity of the research workforce by recruiting and supporting students, postdocs, and eligible investigators from groups that have been shown to be underrepresented in health-related research. Administrative supplements must support work within the scope of the original project.
Due Dates: Feb. 27 (OSR) Mar. 01 (Sponsor)
Additional Due Date:  Dec. 01
Amount & Project Period: See NCI Diversity Supplements Guidelines
Administrative supplements end w/currently funded competitive cycle of parent grant and budget requests may be limited by the awarding IC. Also see terms & conditions in FOA.
Eligibility: Parent grant must have at least 2 years of NCI support remaining;
Candidates for supplement may be students, post-baccalaureate and post-Masters individuals, postdoctoral fellows and faculty investigators who are members of an underrepresented group;
NCI does not accept P30, SC1, SC2 or SC3 as parent grants for Diversity Supplements;
R01 or R01- equivalent grants are allowed to support a maximum of 2 Diversity Supplement candidates;
R21 or R21- equivalent grants are allowed to support a maximum of 1 Diversity Supplement candidate whose career level is graduate student or more junior;
Graduate student and postdoctoral fellow candidates who are receiving support from an agency of the Public Health Service (PHS) at the time of submission are not eligible.
Contact: Office of Sponsored Research (x6804)
Links: PA-18-586
NCI Diversity Supplements Guidelines


NEW
March 01 See Below Non-Federal Melanoma

Melanoma Research Foundation
2018 Request for Applications

The MRF will offer Established Investigator (EIA) and Career Development (CDA) awards and a new grant researching mucosal melanoma (MM-CDA).  The EIA is for established, senior researchers working in closely related fields who wish to move into melanoma research.  The CDA is for researchers beginning a research career focused on melanoma who have not yet established strong federal funding for their research.  The following categories are the identified unmet needs in melanoma research selected as Specific Topic Proposals (STPs) for 2018 (details on each of these categories noted on p.8 of the RFP):
     Prevention: Development of models and biomarkers
     Metastases: Dormancy and metastatic progression
     Response to treatment
Applicants must clearly indicate which category - if any - is being addressed. Although applications are not required to address these STPs, those that do might be given extra consideration.
Due Dates: Feb. 27 (OSR) Mar. 01 (Sponsor)
Amount & Project Period: EIAs: $100,000/yr. - 2 years
CDAs (Incl. MM-CDA): $50,000/yr. - 2 years
Eligibility: General Eligibility:
Applicant must hold a PhD or MD degree or equiv.;
Applicant may be PI or co-PI on only one application of any type;
U.S. citizenship not required, but research must be conducted in the U.S.;
PIs and co-PIs may not have an active research award w/MRF.
EIAs:
Both tenured and on-tenure-track established melanoma researchers, or senior researchers (title equiv. to Assoc. Professor or higher) working in closely related fields who wish to move into melanoma research;
CDAs (Incl. MM-CDA): 
Junior investigators w/<5 years of postdoc experience at time of grant award;
Must not have previously received any major grant support (e.g. from ACS, NIH, NCI or DoD):
Applicants may also have a title of Research Associate/ Scientist, Instructor, Assistant Professor, or equiv. Individuals in this category, may have received previous grant support (e.g. K08, K99, etc.);
Applicant required to have at least one mentor (Mentors do not have to be at applicant's own institution). 
Contact: Office of Sponsored Research (x6804)
RFA Link: 2018 MRF Request for Proposals (RFP)
ProposalCENTRAL (Submission Site)

March 01 Established Women Investigators Non-federal Achievement Award

Federation of American Societies for Experimental Biology (FASEB)
2018 Excellence in Science Award
"Recognizing the Research Accomplishments of Women Scientists"

This award is given in recognition of outstanding achievement by women in biological science.  Recipients are women whose career achievements have contributed significantly to further understanding of a particular discipline by excellence in research.
Due Dates: Mar.  01
Amount & Project Period: $10,000 unrestricted research grant and presentation at the annual meeting of a FSAEB Member Society
Eligibility: Nominators and nominees: must be members of at least one FASEB Member Society but do not have to be members of the same society;
Award recipient required to present an Excellence in Science Award Lecture at the annual meeting of a FASEB Member Society in the award year;
Nominations must be submitted on the Excellence in Science Award nomination form
Contact: Yvette R. Seger, PhD, Director of Science Policy and Staff Liaison to the Excellence in Science Award Committee (301)634-7124
Link: FASEB Excellence in Science Award
Admin. Supplement NCI
March 01 See Below Federal PDX/PDXNet

Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the PDX Development and Trial Centers Research Network (PDXNet)(Admin Supp. Clinical Trial Not  Allowed)  

This FOA is part of the Cancer Moonshot initiative to accelerate cancer research.  As part of this initiative, NCI created the Patient-Derived Xenograft (PDX) Development and Trial Centers Research Network (PDXNet) to accelerate development of NCI investigational new drug (IND) agents (i.e., those that NCI is developing in collaboration with pharmaceutical partners) in NCI-sponsored early phase clinical trials.   This FOA supports supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations between non-PDXNet investigators and PDXNet investigators to perform research within the scientific scope(s) of the parent grant and/or cooperative agreement award(s) that will lead to improved pre-clinical evaluations of novel therapeutic concepts using the large-scale PDX model collections of PDXNet, and that could ultimately be tested in NCI-sponsored clinical trials.
Due Dates: Feb. 27 (OSR) Ι Mar. 01 (Sponsor)
Amount & Project Period: No more than $125,000 (total costs) - 1 year and must be w/in currently approved project period for existing parent award.
Eligibility: Requests must be submitted on paper for the following:
P01 Research Program Projects, P30 Center Core Grants, P50 Specialized Center, U54 Specialized Center- Cooperative Agreements, and UM2 Program Project or Center with Complex Structure Cooperative Agreement
Requests may be submitted electronically for the following:
R01 Research Project Grant, U01 Research Project/Cooperative Agreements, and UM1 Multi-Component Research Project Cooperative Agreements
Contact: Office of Sponsored Research (x6804)
FOA Link: PA-18-496
Admin. Supplement NIH
NCI is a participating Institute
NEW
March 01 See Below Federal Career Development

Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Clinical Trial Not Allowed)

This FOA provides for administrative supplements to research grants to support individuals with high potential to re-enter an active research career after an interruption for family responsibilities or other qualifying circumstances. This program will provide administrative supplements to existing NIH research grants for the purpose of supporting full-time or part-time research by these individuals to update their existing research skills and knowledge.
Due Dates: Feb. 27 (OSR) Ι Mar. 01 (Sponsor)
Additional Due Date:  Dec. 01
Amount & Project Period: Annual Salary Cap: $100,000 plus fringe benefits;
Addnl. $10,000 (Max.) for supplies, domestic travel, and publication costs;
Period of performance must be w/in currently approved period for existing parent award.
Eligibility: See FOA for listing of Activity Codes of eligible awards.
Eligible Candidates:
Must have doctoral degree, (e.g. M.D., D.D.S., Ph.D., O.D., D.V.M., or equiv.); and accepted in a postdoctoral or faculty position at the time they left active research.
Must be planning a career in biomedical, behavioral, or clinical research; (candidates who have begun re-entry process with a fellowship, traineeship, or similar mechanism are not eligible);
Awards limited to citizens or non-citizen nationals of U.S. or to individuals who have been lawfully admitted for permanent residence (i.e., in possession of a Permanent Resident Card, Form I-551) at the time of award.
See FOA: Section 3.Additional Information on Eligibility, Eligibility Circumstances for additional information.
Contact: Office of Sponsored Research (x6804)
Links: PA-18-592
NCI Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers


NEW
March 02 All Faculty Ranks Non-federal Lung Cancer

AACR-Johnson & Johnson
Lung Cancer Innovation Science Grants

Proposals should focus on understanding behaviors that lead to chronic exposures to respiratory carcinogens and how these behaviors can be modified; how chronic exposures produce cellular/genomic damage and how these can be ameliorated; deciphering types of inflammation that underlie the carcinogenic process; understanding alterations in innate and adaptive immunity that create an immune-permissive microenvironment; and changes in the pulmonary microbiome that may contribute to carcinogenesis. Proposals that characterize premalignant lesions or that substantially improve the detection of lung cancer at more curable stages will also be prioritized.
Due Dates: Feb. 28 (OSR) Ι Mar. 02 (Sponsor)
Amount & Project Period: $1.5M (TOTAL) - 3 years
Eligibility: Independent investigators at all levels;
At least 2, but no more than 3, co-applicants serving as Co-PIs from distinct institutions are required (the lead PI is responsible for application);
Only one application per lead PI will be accepted, although individuals may serve as a co-PI or contribute to more than one application;
Principal Investigators (PIs) must have a doctoral degree (including PhD, MD, DO, DC, ND, DDS, DVM, ScD, DNS, PharmD, or equiv.) in biomedical sciences or a field applicable to health science research;
Project Team should also include at least 1 young investigator (e.g., postdoctoral or clinical research fellow; junior faculty member);
Non-citizens or permanent residents must assure that visa status will provide sufficient time to complete project and grant term at institution from which application submitted;
AACR membership is required.  Satisfactory membership application must be submitted by Friday, March 2, 2018.
Contact: Office of Sponsored Research (x6804)
Links: AACR-J&J Lung Cancer Innovation Science Grants
Program Guidelines and Application Instructions
proposalCENTRAL (Submission Site)
See Below NIH
NIH Common Fund/Roadmap Initiatives
Administered by NCATS
NEW
(See 5 related RFAs listed below)
March 03 (LOI) All Ranks Federal Genome Editing

Somatic Cell Genome Editing Program

This program will fund projects to, "...improve the delivery mechanisms for targeting gene editing tools in patients, develop new and improved genome editors, develop assays for testing the safety and efficacy of the genome editing tools in animal and human cells, and assemble a genome editing toolkit containing the resulting knowledge, methods, and tools to be shared with the scientific community...." (Tuesday, 1/23/218 NIH News releases NIH to launch genome editing research program).  There are five RFAs listed below.
Due Dates: Mar. 03 (Letter of Intent)
Applications Due: Mar. 30 (OSR) Ι Apr. 03 (Sponsor)
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
U42 NIH

Rodent Testing Centers for Development of Reporter Systems and Evaluation of Somatic Cell Genome Editing Tools (Clinical Trial Not Allowed)

The purpose of this FOA is to create rodent reporter models for testing in vivo genome editing technologies, and to use these animal models to test genome editing delivery technologies and new genome editors developed under RFA-RM-18-016 and RFA-RM-18-017. The deliverables from the initiative will be a set of animal models (mice and rat), containing one or more reporter genes expressed in all cell types, that will allow facile and quantitative evaluation of genome editing in any cell type of interest.
Amount & Project Period: $225,000 (Direct Costs Yr. 01) and
$450,000 (Direct Costs Yrs. 2-5) - 5 years
RFA Link: RFA-RM-18-012
U01 NIH

Development of Cell and Tissue Platforms to Detect Adverse Biological Consequences of Somatic Cell Genome Editing (Clinical Trial Not Allowed)

The purpose is to solicit applications proposing to develop and validate tissue- and cell-based platforms for assessing potential adverse biological consequences of somatic cell genome editing.
Amount & Project Period: $390,000/yr. (Direct Costs) - 5 years
RFA Link: RFA-RM-18-015
UG3/UH3 NIH

Innovative Technologies to Deliver Genome Editing Machinery to Disease-relevant Cells and Tissues (Clinical Trial Not Allowed)

The purpose is to support development and evaluation of innovative approaches to deliver genome editing machinery into somatic cells, with the ultimate goal of accelerating development of genome editing therapeutics to treat human disease.
Amount & Project Period: $500,000/yr. (Direct Costs yrs. 1-3)                              $1,000,000/yr. (Direct Costs yrs. 4&5)
RFA Link: RFA-RM-18-016
U01 NIH

Expanding the Human Genome Editing Repertoire (Clinical Trial Not Allowed)

The purpose is to solicit applications proposing research on development of novel and optimized alternatives to existing in vivo genome editing complexes.
Amount & Project Period: Not to exceed $250,000/yr. (Direct Costs) - 5 years
RFA Link: RFA-RM-18-017
U24 NIH

Somatic Cell Genome Editing Dissemination and Coordinating Center
(Clinical Trial Not Allowed)

The purpose is to support establishment of a Dissemination and Coordinating Center (DCC) for the NIH Somatic Cell Genome Editing (SCGE) Consortium. In addition to this DCC, the Consortium will include four components (genome editing tools, delivery systems, animal models and biological assays) to produce validated techniques and knowledge through exchange of expertise, information and research tools. The DCC is expected to interact with other components of the SCGE Consortium to facilitate collaborative activities within the entire Consortium. The DCC will develop an online platform to facilitate information sharing within the Consortium, assemble resources (tools, methods, data and best practices) generated from all Consortium components into a SCGE Toolkit for Therapeutic Genome Editing, and disseminate the SCGE Toolkit and other appropriate resources to researchers across the biomedical research community.
Amount & Project Period: Direct Costs:  $1.25M/yr.01; $3.25M/yrs. 2-4; and $1.0M/yr.05 - 5 years
RFA Link: RFA-RM-18-018

NEW
March 5 (Pre-application) All Ranks Non-federal Health Disparities

Rita & Alex Hillman Foundation
Hillman Innovations in Care Program

Innovations in Care supports programs that improve the health and health care of vulnerable populations, including economically disadvantaged, racial and ethnic minorities, LGBTQ people, the homeless, rural populations, and others.. The 2018 RFP seeks applications from nursing-driven, evidence-based, patient- and family-centered initiatives that challenge conventional strategies, improve health outcomes, lower costs, and show potential for national replicability.
Due Dates: Mar. 05 (Pre-application)
Invited Submissions:  May 31 (OSR) Ι June 04 (Sponsor) Submissions must be made online at http://www.rahf.org/grants
Amount & Project Period: $600,000 - 3 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
Links: Hillman Innovations in Care Program Ι Request for Proposals
R01 NIH
NCI is a participating Institute NEW
March 05 (LOI) All Ranks Federal Liver

Mechanisms of Disparities in Chronic Liver Diseases and Cancer

The purpose of the initiative is to support multidisciplinary research to understand the underlying etiologic factors and the mechanisms that result in disparities in chronic liver diseases and cancer in the US.
Due Dates: Mar. 05 (Letter of Intent, not required or binding)
Apr. 02 (OSR) Ι Apr. 04 (Sponsor)
Additional Due Date:  Apr. 04, 2019
Amount & Project Period: Application budgets not limited - 5 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-17-151
Companion FOA: PAR-17-150 R21
K18 NIH
NCI is a participating Institute
March 06 All Ranks Federal Career Enhancement Award

Short-term Mentored Career Enhancement Awards for Mid-Career Investigators to Integrate Basic Behavioral and Social Sciences (No Independent Clinical Trials)

This FOA encourages applications for short-term mentored career development (K18) awards that improve synergies among researchers in basic and applied behavioral-social sciences, human subjects and model animals settings; and biomedical and behavioral-social sciences. It is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.
Due Dates: Mar. 02 (OSR) Ι Mar. 06 (Sponsor)
Additional Due Date: Mar. 06, 2019
Amount & Project Period: May not exceed $100,000 (Total Costs) - 1 year
See FOA for specific costs supported
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-349
NEW
March 09 All Ranks Non-federal Women's Health

Patty Brisben Foundation for Women's Health
2018 Grant Cycle

 Supports research on side effects of cancer treatments affecting women's sexual health.
Due Dates: Mar. 07 (OSR) Ι Mar. 09 (Sponsor)
Amount & Project Period: Not stated
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
Link: Apply for Funding


NEW
March 12 All Moffitt Faculty Moffitt Research Projects

Miles for Moffitt Funding Opportunity

Research leadership is pleased to announce the annual Miles for Moffitt Milestone Awards funding opportunity. Investigators are invited to apply for pilot funding with a goal to develop a competitive extramural proposal. Applications related to the best scientific criteria are specifically encouraged. Must be a new project, not continuation or extension of something already in progress.
Due Dates: All applications (full proposal, budget and budget justification) along with the Institutional Proposal Submission Forms must be submitted to the Office of Sponsored Research through normal proposal review procedures by March 8th. OSR will submit applications to the Intramural Programs via email by 4:00 pm EST on the due date of March 12th.
Amount & Project Period: $100,000 - 1 year
Eligibility: Established investigators and junior faculty
Current 2017 Miles for Moffitt awardees are not eligible.
Faculty members are limited to only one application submission as the PI and Co-PI, but may be listed as co-investigators on additional applications.
An extramural grant application based on an M4M award is expected to be submitted w/in 12 months of M4M project completion.
Contact: Maureen Ahearn (x8824)
Links: Guidelines Ι Application
R21 NCI

March 12 (LOI) All Ranks Federal Cancer Prevention/Control

Predicting Behavioral Responses to Population-Level Cancer Control Strategies (Clinical Trial Optional)

The goal is to facilitate research to identify individual influences on the effectiveness of population-level strategies that target cancer-related behaviors.
Due Dates: Mar. 12 (Letter of Intent, not required, not binding)
Apr. 09 (OSR) Ι Apr. 11 (Sponsor)
Additional Due Dates: Oct. 10, & Apr. 11, 2019 (w/LOI 30 days prior)
Amount & Project Period: $275,000 (Direct Costs) - 2 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-024
R01 NCI
March 12 (LOI) All Ranks Federal Health Outcomes

Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (Clinical Trial Optional)

This FOA invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.
Due Dates: Mar. 12 (Letter of Intent, not required, not binding )
Apr. 09 (OSR) Ι Apr. 11 (Sponsor)
Additional Due Dates: Oct. 10, & Apr. 11, 2019 (w/LOI 30 days prior)
Amount & Project Period: Application budgets are not limited - 5 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-246
Companion FOA: PAR-18-247  (R21 Clinical Trial Optional)

NEW
March 13 (LOI) Faculty Ranks Non-federal Cell and Gene Therapy

Alliance for Cancer Gene Therapy (ACGT)
2018 Investigator's Award in Cell and Gene Therapy for Cancer

This award is for those conducting cell and gene therapy research in the following areas:
1.    Technology for systemic delivery and treatment of metastatic disease that could involve
        novel tumor-targeted delivery vehicles (e.g. tumor-homing cells, nanoparticles and new
        recombinant viruses).
2.    Altering tumor cell microenvironment to support induction of anti-tumor immunity.
3.    Identification of novel tumor targets.
4.    Novel approaches to either protective adoptively transferred cells from metabolic  
        changes or alter metabolism of transferred cells.
Preference will be given to those working in solid tumors, orphan tumors or pediatric tumors, and to research not previously funded, thus highly innovative proposals.
Due Dates: Mar. 13, 11am, EST (Letter of Intent)
Invited Applications:  May 11 (OSR) Ι May 15, 11am, ET (Sponsor)
Amount & Project Period: Max. $500,000 (TOTAL) - 2 to 3 years
Eligibility: Must be tenure-track or tenured faculty
No citizenship restrictions; work conducted in U.S.
Contact: Office of Sponsored Research (x6804)
Link: proposalCENTRAL Ι ACGT


March 14 Junior Faculty Non-federal Brain

The Sontag Foundation
The Distinguished Scientist Award (DSA)

This award provides career and research support to early career scientists demonstrating outstanding promise for making scientific and medical breakthroughs in brain cancer research. Awarded projects will show potential to generate new knowledge relating to causes, cure or treatment of primary brain tumors/brain cancer.
Due Dates: Mar. 12 (OSR) Ι Mar. 14
Amount & Project Period: $600,000 - 4 years
Eligibility: Must have received first faculty appt. no earlier than March 1, 2013 w/in U. S. or an equiv. institution in Canada.  If tenure-granting institution, appt. must be tenure-track.
Contact: Office of Sponsored Research (x6804)
Link: DSA Application Information and Requirements


NEW
March 15 Physician Researchers Non-federal Diversity Career Development

Robert Wood Johnson Foundation
Harold Amos Medical Faculty Development Program (AMFDP)

The purpose of this program is to increase the number of faculty from historically disadvantaged backgrounds who can achieve senior rank in academic medicine. The program defines the term "historically disadvantaged" to mean challenges facing individuals because of their race, ethnicity, socioeconomic status, or similar factors (e.g., possession of a physical, learning, or other disability; first-generation college graduate).
Due Dates: Mar. 13 (OSR) Ι Mar. 15 (Sponsor) In addition to electronic submission, a hard copy must be postmarked by Mar. 16.
Amount & Project Period: $420,000 - 4 years
Eligibility: Must be from historically disadvantaged background (see above);
Must be U.S. citizen or permanent resident at time of application (see announcement for Deferred Action for Childhood Arrivals ("DACA") status;
Must be completing or have completed formal clinical training; Physicians must be Board-eligible to apply;
Expectation is that at least 70% effort will be dedicated to research.
Contact: Office of Sponsored Research (x6804)
Links: Overview | 2018  Call for Applications

March 15 Junior Faculty Non-federal Neuromodulation

AAAS/SCIENCE and Beijing PINS Medical Equipment Co. Ltd.
Science & PINS Prize for Neuromodulation

The Science & PINS Prize for Neuromodulation is a highly competitive prize which honors scientists for their excellent contributions to neuromodulation research.
Due Dates: March 15 (Sponsor)
Amount & Project Period: $25,000 and publication of essay in Science (See link for details)
Eligibility: Must be Junior Investigator w/advanced degree rec'd. w/in last 10 years, and must be 45 years or younger as of 01/01/2018;
Entrant's essay must describe research and its implications for neuromodulation.
Entrant must have performed or directed work described in essay.
Research must have been performed during previous 3 years.
Contact: SciencePINSPrize@aaas.org
Links: About the Prize | How to Enter

March 15 Postdocs Non-federal Career Development

Damon Runyon Cancer Research Foundation
Fellowship Awards

This fellowship award supports all theoretical and experimental research relevant to the study of cancer and the search for cancer causes, mechanisms, therapies, and prevention.
Due Dates: Mar. 13 (OSR) Ι Mar. 15 (Sponsor)
Note:  This due date is for degrees conferred April 15, 2017 - March 15, 2018, and applicant joined lab on or after April 15, 2017.
Amount & Project Period: $231,000 - 4 years
Eligibility: Applicants must have completed one or more of the following degrees or its equiv.: (MD, PhD, MD/PhD, DDS, and/or DVM).
See Award Overview/Eligibility for additional details.
Contact: Office of Sponsored Research (x6804)
Links: Awards Program Information Ι Award Application Guidelines
R21/R33 NIH
NCI is a participating Institute
NEW
March 16 All Ranks Federal Aging

Research Infrastructure Development for Interdisciplinary Aging Studies (Clinical Trial Optional)

The purpose is to support advanced-stage development and utilization of novel research infrastructure to advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Exploratory/Developmental Grants Phase II mechanism to provide support for expanded activities.  Through this award, investigators will develop a mature and sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.
Due Dates: Mar. 14 (OSR) Ι Mar. 16 (Sponsor)
Additional Due Dates:  Standard dates
Amount & Project Period: R21 Phase:  $275,000 (Direct Costs) - 2 years
R33 Phase:  Under $500,000/yr.  (Direct Costs) - 3 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-645
Companion FOA: PAR-18-644  R33 (Exploratory/Developmental Grants Phase II)


March 19 Junior Faculty Non-federal Career Development

Prostate Cancer Foundation
2018 Young Investigator Awards

Research proposals submitted in consideration for this award should, if successful, provide high impact to the field. "Small-step" or incremental proposals are usually non-competitive. Highly innovative basic science programs will be carefully considered, but priority will be given to "bench to bedside" translational research proposals w/potential to deliver near term benefit to patients. Successful applicants should be working in a research environment capable of supporting transformational prostate cancer research. Access to and interaction with a clinical environment and translational prostate cancer physician-scientists is highly desired.
Due Dates: Mar. 15 (OSR) Ι Mar. 19 (Sponsor)
Amount & Project Period: $225,000 - 3 years
Eligibility: S/be w/in 6 years following completion of a professional degree;
Must hold title of Postdoc, Instructor, Research Associate, Asst. Professor or equiv.;
Must be under direct supervision of a mentor(s) and at least 1 mentor must reside at applicant's institution;
S/have received no more than $200,000 in current direct research funding from all sources including institutional funds during the 3-year term of this award
Contact: Office of Sponsored Research (x6804)
RFA Link: RFA

NEW
March 19 Graduate Students/Postdocs Non-federal Career Development/Travel Support

Lymphatic Education & Research Network (LE&RN)
LE&RN Travel Awards 20th International Vascular Biology Meeting in Helsinki

Travel awards are being offered to defray registration and travel costs associated with attendance at the 2018 meeting.
Due Dates: Mar. 19 (Sponsor)
Amount & Project Period: Support to defray registration and travel costs associated with attending the 20th International Vascular Biology Meeting in Helsinki, Finland (June 3-7, 2018).
Eligibility: Must be actively enrolled in a doctoral program, residency or accredited program of postdoctoral graduate education in the biomedical sciences. Other trainees will be considered at the discretion of LE&RN and the Review committee;
Must be a current LE&RN supporting member in good standing through December 31, 2018 or later (become a Supporting Member here)
Contact: Please contact LE&RN at lern@lymphaticnetwork.org.
Links: LE&RN Travel Awards
20th International Vascular Biology Meeting in Helsinki, Finland (June 3-7, 2018)
Research Alliance of the
Eastern Cooperative Oncology Group (ECOG) &
American College of Radiology Imaging Network (ACRIN)
NEW
March 23 Postdocs Non-federal Clinical Career Development

ECOG-ACRIN Cancer Research Group
Eastern Cooperative Oncology Group (ECOG)
Paul Carbone, MD Fellowship Award

The purpose of this award is to develop and promote excellence in clinical trials leading to improvements in cancer care.
Due Dates: Mar. 21 (OSR) Ι Mar. 23 (Sponsor)
Amount & Project Period: $25,000 - 1 year
Eligibility: Must meet all of the following criteria:
Completed two years of a fellowship in oncology or hematology at an ECOG-ACRIN member institution before the award's effective date of July 1;
Must be actively involved in a cancer clinical trial and planning to conduct related research activity in the upcoming year;
Not yet appointed to a first full-time faculty position as of the award effective date
Contact: Office of Sponsored Research (x6804)
Link: Paul Carbone, MD Fellowship Award


April 01 All Faculty Ranks Non-federal Leukemia

When Everyone Survives Leukemia Research Foundation
2018 Request for Proposals in Leukemia Research  

This RFP solicits innovative research in leukemia and provides support for laboratory, translational, or clinical research related to acute leukemia.
Due Dates: Mar. 28 (OSR) Ι Apr. 01 (Sponsor- Receipt Date)
Amount & Project Period: $50,000 (Total Costs) - 1 year  
Eligibility: New and established investigators 
Contact: Office of Sponsored Research (x6804)
Link: Guidelines
   

April 01 All Faculty Ranks Non-federal Brain

B*CURED
2018 Research Investigator Grant Program

Clinical doctors and research scientists whose primary focus is brain cancer are invited to apply for a grant. Clinical and translational projects with significant clinical promise will be considered. Both adult and pediatric brain cancer projects will be considered.
Due Dates: Mar. 28 (OSR) Ι Apr. 01 (Sponsor)
Amount & Project Period: $50,000 - 1 year
Eligibility: All Faculty Ranks - must be:
Undertaking clinical or translational research, w/intention of applying for R01 NIH funding or equivalent w/in 5 years, or Undertaking innovative research to bridge from bench to animal research or to acquire preclinical data from animal models; Formal involvement of a biostatistician is required for all clinical trial proposals, but not for pre-clinical or translational science proposals.
Contact: Office of Sponsored Research (x6804)
Links: 2018 Research Investigator Grant Ι FAQs


Spring Cycle
April 02 See Below Non-federal See Below

American Cancer Society - Spring 2018

 
Due Dates: Mar. 29 (OSR) Ι Apr. 02 (Sponsor)
Contact: Office of Sponsored Research (x6804)
Primary Link: proposalCentral

Clinician Scientist Development Grant (CSDG)

 This grant fosters development of clinicians to clinician scientists. Clinician scientists are investigators licensed to provide patient care and trained to conduct research. They pursue research questions across the cancer research continuum of relevance to improving health.
Amount & Project Period: $135,000/yr. (Direct Costs) - 3 to 5 years
Eligibility: Must be full-time and w/in first 6 years of initial faculty appointment. Must be U.S. citizen or permanent resident of U.S. (See Eligibility, section 21 of the Grant Policies and Instructions for more information).
Links: Overview Ι Grant Policies and Instructions

Postdoctoral Fellowships

Supports training of researchers who have received a doctoral degree to provide initial funding leading to an independent career in cancer research (including basic, preclinical, clinical, cancer control, psychosocial, behavioral, epidemiology, health services and health policy research).
Amount & Project Period: Stipends of $48,000, $50,000, and $52,000 per year, plus a $4,000 per year fellowship allowance – 3 years
Eligibility: Must be U.S. citizen or permanent resident of U.S.
Links: Overview Ι Policies and Instructions

Mentored Research Scholar Grant

NOTE: This mechanism is being phased out. Only resubmissions will be reviewed in 2018. Provides support for mentored research and training to full-time junior faculty, typically within the initial four years of their first independent appointment. The goal is for these beginning investigators to become independent researchers as either clinician scientists or cancer control and prevention researchers.
Amount & Project Period: $135,000/yr. (Direct Costs) -5 years
Eligibility: Junior faculty w/in first 4 years of first independent appointment. (See Eligibility, section 21 of the Grant Policies and Instructions for more information).
Links: Overview Ι Policies and Instructions
 

Pilot and Exploratory Projects in Palliative Care of Cancer Patients and Their Families

This RFA is limited to applications that focus on palliative care research projects for seriously ill cancer patients and their families in three specific areas: 1. Exploring the relationship of pain and other distressing symptoms on quality and quantity of life, independence, function, and disability and developing interventions directed at their treatment in patients with advanced and chronic illnesses; 2. Studying methods of improving communication between adults living with serious illness, their families and their health care providers; 3. Evaluating models and systems of care for patients living with advanced illness and their families.
Amount & Project Period: $60,000/yr. (Direct Costs) - 1 to 2 years
Eligibility: All Faculty Ranks - Must have Full-time faculty position
Links: Overview
Pilot and Exploratory Projects in Palliative Care of Cancer Patients and  Their Families Policies and Instructions.


New Initiative
April 02 (LOI) See Below Non-federal See Below

American Cancer Society
New Initiative: Mission Boost Grants (MBG)

The purpose is to support select current and past ACS grantees specifically for translation of their research to human testing. These grants are opportunities for ACS grantees to seek additional, or "boost" resources for innovative, high-risk/high-reward projects. MBGs offer 2 stages of funding:
The Primary Boost requires development of outcome-specific, unequivocal milestones that reduce risks of studying a new drug, device, or procedure in patients. The topic of study may be the same that was previously funded by the ACS grant, but it doesn't have to be. Primary MBG studies can be preclinical or clinical in nature.
The Secondary Boost requires the investigator to have successfully completed the Primary Boost milestones and submitted them to the Extramural Council for permission to move forward with this grant. The investigator may apply for a Secondary Boost grant to receive support for an additional period for advancing the research to clinical testing in cancer patients. Secondary MBG studies must involve testing in cancer patients.
The focus of the Mission Boost Program  To be considered for an MBG, research projects must focus on studies in cancer patients, such as:
   Treatment - First Time in Humans (FTIH); clinical proof-of-concept (PoC); side effect
   reduction;
   Diagnostics/Prognostics/Medical Devices – Clinical validation in humans;
   Prevention - Including initial incidence or recurrence in humans (biomarker  
   based/biomarker testing)
Due Dates: Apr. 02 (Letter of Intent)
Jul. 12 (OSR) Ι Jul. 16 (Sponsor)
Amount & Project Period: The Primary Boost: $200,000 (Direct Costs) -2 years
The Secondary Boost: $300,000 (Direct Costs) - 18 months
Eligibility: Must have held or currently hold one of these grants (or previous versions of such awards): Research Scholarship Grant (RSG), Mentored Research Scholar Grant (MRSG), Cancer Control Career Development Awards (CCCDA), or Pilot and Exploratory Projects in Palliative Care (PEP) award for a minimum of one year. Note: For current ACS grantees, recommendation is to delay submission of letter of intent (LOI) until last year of grant since part of the LOI review may include consideration of discoveries made under ACS support.
Currently independent, full-time faculty
Who's Not Eligible: People who have had only grants for ACS Postdoctoral Fellows or ACS Professors, without also having one of the grant types listed above.
Contact: Office of Sponsored Research (x6804)
Links: New Initiative Ι proposalCENTRAL (Submission site)


April 02 Postdocs Non-federal Immunology/Tumor Immunology

Cancer Research Institute Irvington
Postdoctoral Fellowship Program

The Institute seeks hypothesis-driven, mechanistic studies in both immunology and tumor immunology. Application must clearly state potential of proposed studies to directly impact understanding of the immune system's role in cancer risk, tumor initiation, progression, metastasis, host response to tumors and/or the treatment of cancer.
Due Dates: Mar. 29 (OSR) Ι Apr. 02 (Sponsor)
Additional 2017 Due Date:  Oct. 01
Amount & Project Period: 3 years
Annual Stipend:  $55,000, $57,000 & $59,000
Institutional Allowance:  $1,500/yr.
Eligibility: Must have doctoral degree by award activation;
Must have < 5 years' postdoc experience;
Must have < 3 years' experience in sponsor lab at award activation
Contact: Office of Sponsored Research (x6804)
RFA Link: Program Description Ι Instructions
R43/R44 NIH
NCI is a participating Institute

NEW
April 05 Small Business Concerns (SBCs) Federal SBIR

PHS 2018-02 Omnibus Solicitation of the NIH for Small Business Innovation Research Grant Applications (Parent SBIR Clinical Trial Required)

This FOA invites eligible U.S. Small Business Concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications in response to identified topics (see PHS 2018-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed.
Due Dates: Apr. 05 (Sponsor)
Additional Due Dates:  Standard Dates
Amount & Project Period: Phase I:  $150,000 - 6 months
Phase II: $1,000,000 - 2 years
See FOA for detailed information about research split between SBC and partnering research institution.
Eligibility: Only United States small business concerns (SBCs) are eligible. (See FOA, Section II).
Primary employment of the PD/PI (for both Phase I and Phase II) must be w/SBC at time of award and during conduct of proposed project. For projects w/multiple PDs/PIs, at least one must meet primary employment requirement.
See SBIR/STTR Application Guide for specific details on eligibility requirements.
Contact: Office of Sponsored Research (x6804)
FOA Link: PA-18-573  (R43/R44 Small Business Innovation Research (SBIR) Grant - Phase I, Phase II, and Fast-Track)
Companion FOA: PA-18-574 (Clinical Trial Not Allowed) (R43/R44 Small Business Innovation Research (SBIR) Grant - Phase I, Phase II, and Fast-Track)
R41/R42 NIH
NCI is a participating Institute
NEW
April 05 Small Business Concerns (SBCs) Federal Small Business Technology Transfer (STTR)

PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Technology Transfer Grant Applications (Clinical Trial Not Allowed)(Parent STTR)

This FOA invites eligible U.S. Small Business Concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications in response to identified topics (see PHS 2018-2 SBIR/STTR Program Descriptions and Research Topics for NIH.
Due Dates: Apr. 05 (Sponsor)
Additional Due Dates:  Standard Dates
Amount & Project Period: Phase I:  $150,000 – 1 year
Phase II: $1,000,000 – 2 years
See FOA for detailed information about research split between SBC and partnering research institution.
Eligibility: Only United States small business concerns (SBCs) are eligible (See FOA, Section III).
PD(s)/PI(s) may be employed w/SBC or the single, "partnering" non-profit research institution as long as s/he has a formal appointment with or commitment to the applicant SBC, characterized by an official relationship with the SBC.
Each PD/PI must commit a minimum of 10% effort and have formal appointment with or commitment to applicant SBC, characterized by an official relationship between the SBC and that individual. Such a relationship does not necessarily involve a salary or other form of remuneration.
Contact: Office of Sponsored Research (x6804)
FOA Link: PA-18-575 (R41/R42 Small Business Technology Transfer (STTR) Grant - Phase I, Phase II, and Fast-Track)
Companion FOA: PA-18-576 (Clinical Trial Required) (R41/R42 Small Business Technology Transfer (STTR) Grant - Phase I, Phase II, and Fast-Track)
R43/R44 NCI

April 05 Small Business Concerns (SBCs) Federal Cancer Relevant Technologies

Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (Clinical Trial Not Allowed)  

This FOA invites SBIR grant applications from small business concerns (SBCs) proposing research for commercial development of novel cancer-relevant technologies. Proposed research projects are expected to focus on development of highly-innovative technologies that improve molecular and/or cellular analysis of cancer with a significant likelihood for either overcoming persistent challenges or obstacles or opening entirely new fields for cancer research or clinical care. Applications should specify milestones relevant to both development and commercialization of these technologies. Applications are expected to indicate the significant attributes and advantages of the proposed technology over currently available technologies and conventional approaches.
Due Dates: April 05 (Sponsor)
Additional Due Dates:  Standard dates
Amount & Project Period: Phase I awards:  $150,000 - normally not to exceed 6 mos.
Phase II awards: $1,000,000 - normally not to exceed 2 years
Eligibility: Only U.S. small business concerns (SBCs) are eligible to submit applications (See FOA for details).
Primary employment of PD/PI must be w/SBC at the time of award and during conduct of proposed project. For projects with multiple PDs/PIs, at least one must meet primary employment requirement. Occasionally, deviations from this requirement may occur.
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-303

NEW
April 06 (Required Registration) All Ranks Non-federal HIV/AIDS

amFAR, The Foundation for AIDS Research
Impact Grants: Gaining Insights from the Clinic  

The goal of the RFP is to generate practical, implementable information to facilitate design and interpretation of broadly generalizable HIV cure clinical research.  Specific areas of interest are to: (1) Identify pre-ATI predictors of post-treatment control (PTC) or delay to rebound; and (2) Diversify the HIV cure clinical study population.
Due Dates: Must Register by April 06, by 12:00pm ET (REQUIRED) to provide preliminary information and to receive portal username, password and other Letter of Intent materials.
Apr. 11, 3:00pm, ET (Letter of Intent)
Invited Submissions:  Early August 2018
Amount & Project Period: 1.1: Meta-analysis of data from completed clinical trials (1 year; Total Costs: $100,000)
1.2: Addition of study arm to an existing clinical trial (4 years; Total Costs: $300,000)
1.3: Addition of reservoir and outcome (PTC or delay to rebound) analyses to an existing clinical trial (4 years; Total Costs: $100,000)
2.1: Addition of a recruitment and retention intervention to an existing clinical trial (4 years; Total Costs: $50,000)
2.2: Characterization of clinical case studies (1 year; Total Costs: $75,000)
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
Links: Impact Grants
Detailed Information about Funding Opportunities
RFP

April 08 See Below Non-federal Career Development

American Society for Radiation Oncology
ASTRO 2018 Funding Opportunities

RFAs for the 2018 grant cycle will open on January 15, 2018.  Below is information on the grants available. Please note that the Full RFAs and submission information will be available on proposalCENTRAL on January 15.
Due Dates: Apr. 05 (OSR) Ι Apr. 08 (Sponsor)
Eligibility: Must have < 5 years in a faculty appointment at time of application, and be an ASTRO member in good standing;
Must attend at least 1 ASTRO Annual Meeting and the BCRF Research Meeting and present findings of this research study at both meetings;
At least 50% full-time professional effort must be devoted to goals of award.
More details will be contained in RFA
Contact: Office of Sponsored Research (x6804)
RFA Link: ASTRO 2018 Funding Opportunities

ASTRO-BCRF Career Development Award to End Breast Cancer

Research must be focused on understanding or treatment of breast cancer and include use or impact of radiation treatment.
Amount & Project Period: $200,000 - 2 years (to be combined with matching funds or in kind contribution from applicant's institution.)
RFA Link: ASTRO-BRCF CDA

ASTRO-PCF Career Development Award to End Prostate Cancer

Research must be focused on understanding or treatment of prostate cancer and include use or impact of radiation treatment.
Amount & Project Period: $225,000 - 3 years (to be combined with matching funds or in kind contribution from applicant's institution.)
RFA Link: ASTRO-PCF CDA


Updated Submission Deadline
April 09 All Faculty Ranks Non-federal Lung

CHEST Foundation
2018 Grant Cycle

Projects supported by the CHEST Foundation lead to breakthroughs in treatment of chest diseases and patient care. Higher-level translational research project is preferred (T1-T5; for definitions, please see: https://ctsi.mcw.edu/images/CTSI Translational-Continuum.pdf); basic (cellular or animal) research projects will not be considered.
Due Dates: Apr. 07 (OSR) Ι Apr. 09 (Sponsor- Receipt date)
Eligibility: CHEST membership required at application;
Licensed physicians; Physicians-in-training (residents or fellows), other health-care professionals, or clinical researchers w/relevant experience also be accepted;
Special consideration is given to young investigators and applicants in early stages of their careers.
Contact: Office of Sponsored Research (x6804)
Primary Link: 2018 RFPs
 

Research Grant in Women's Lung Health

Applications must address important and timely issues surrounding women's lung health, including but not limited to diseases such as COPD and lung cancer.
Amount & Project Period: $10,000 (Total Costs) - 1 year
Link: Women's Lung Health
 

Research Grant in Lung Cancer

Applications must address research that leads to improved medical and/or surgical detection, treatment, and/or cure of lung cancer. Higher-level translational research project preferred (T1-T5; for definitions, please see: https://ctsi.mcw.edu/images/CTSI Translational Continuum.pdf); basic (cellular or animal) research projects will not be considered.
Amount & Project Period: $60,000 - 2 years
Link: Research Grant in Lung Cancer
UG3/UH3 NCI

April 09 (LOI) All Ranks Federal Cancer Therapy

Quantitative Imaging Tools and Methods for Cancer Therapy Response Assessment (Clinical Trial Optional)

This FOA encourages applications to address development, optimization and validation of quantitative imaging (QI) software tools and methods for prediction and/or measurement of response to cancer therapies or for planning and validating radiation therapy treatment strategies in clinical trials. The scientific scope includes:
1. Development and optimization of QI tools and/or methods for treatment planning, predicting or measuring response to therapy as open source tools that will translate into clinical trial decision support;
2. Validation of the optimized tools in clinical settings to demonstrate their value for decision support in ongoing single-site or multi-site clinical trials.
A phased approach that emphasizes each of these activities must be proposed. Investigators must apply for both the UG3 and UH3 phases together in the single application.
Due Dates: Apr. 09 (Letter of Intent, Not required, or binding)
May 07 (OSR) Ι May 09 (Sponsor)
Additional 2018 Due Date:  Sept.12th
Amount & Project Period: UG Phase:  Not to exceed $300,000/yr. (Direct Costs) - 2 years;
UH Phase:  Not to exceed $500,000/yr. (Direct Costs) - 3 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-248
Companion FOA: PAR-18-249 (U01 Clinical Trial Optional)
R01 NCI
NEW
April 11 All Ranks Federal "Chemobrain"

Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (Clinical Trial Optional)

This FOA encourages transdisciplinary research that will leverage cognitive neuroscience to improve traditional measurement of cognitive impairment following cancer treatment, often referred to as "chemobrain."
Due Dates: Apr. 09 (OSR) Ι Apr. 11 (Sponsor)
Additional Due Dates:  Oct. 10, 2018 and Apr. 11, 2019
Amount & Project Period: Budgets not limited - 5 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-605
Companion FOA: PAR-18-606 (R21)
U01 NIH
NCI is a participating Institute
NEW
April 11 All Ranks Federal NIH Collaborative Research

Opportunities for Collaborative Research at the NIH Clinical Center (Clinical Trial Optional)

This FOA supports collaborative translational research projects to enhance translation of basic biological discoveries into clinical applications that improve health.  Specifically it seeks to broaden and strengthen translational research collaborations between basic and clinical researchers within and outside of NIH by providing support for extramural investigators to take advantage of unique research opportunities available at the NIH Clinical Center by conducting research projects in collaboration with NIH intramural investigators.  See NCI specific area of interest in FOA.
Due Dates: Apr. 09 (OSR) Ι Apr. 11 (Sponsor)
Amount & Project Period: Max. $500,000/yr. (Direct Costs (total for extramural grantee, Clinical Center and Intramural investigator)) - 4 years
Eligibility: All Ranks - Application requires full collaboration of extramural PD/PI from applicant institution and NIH intramural investigator. 
Multiple PD/PI (MPI) model is strongly encouraged but not required.  For applicants opting to not use MPI model, NIH intramural investigator can hold any role other than PD/PI role.
Contact: Office of Sponsored Research (x6804
FOA Link: PAR-18-646
R13 NIH
NCI is a participating Institute
NEW
April 12 All Ranks Federal Conference/Meeting Support

NIH Support for Conferences and Scientific Meetings (Parent FOA - Clinical Trial Not Allowed)

The purpose is to support high quality conferences relevant to the public health and to the scientific mission of the participating Institutes and Centers.
Due Dates: Apr. 10 (OSR) Ι Apr. 12 (Sponsor)
Additional Due Dates:  Standard dates
Amount & Project Period: The appropriate NIH Conference Grant Contact should be consulted for guidance regarding any IC-specific budget limitations or project duration requirements.  Most ICs will accept applications for up to 5 years if a series of annual or biannual conferences are proposed by a permanently sponsoring organization. Support for conferences held on a less frequent schedule must be applied for individually.
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PA-18-648

April 15 All Ranks Non-federal Bridge Funding

Rivkin Center for Ovarian Cancer
Bridge Funding

Bridge Funding allows researchers to produce data needed to substantiate a proposal resubmission to federal funding agencies. Interim funding is provided to researchers who have submitted an R01 or R21 proposal to the NIH or an original proposal to the Department of Defense (DoD) pertaining to ovarian cancer, have not received but were close to, a fundable score.  Investigator-initiated projects in all areas of ovarian cancer research are eligible. Special consideration will be given to research that has clinical applicability. .
Due Dates: Mar. 28 (OSR) Ι Apr. 15 (Sponsor)
Additional Due Date:  Oct. 15
Amount & Project Period: $30,000 - (Must have a duration of at least 6 months prior to resubmission to a federal funding agency)  
Eligibility: All Ranks
Unfunded first submission NIH R01, R21, K08, K23, and K99 proposals (no A1 or A2 proposals) as well as original DoD proposals are eligible.
NIH proposals must have scored in the 20th percentile or lower, and DoD proposals must have scored less than 2.5.
Must have received agency score w/in past 9 months and must require at least 6 months of additional research prior to resubmission.
Contact: Office of Sponsored Research (x6804)
Links: Award Guidelines Ι RFA

NEW
April 16 Faculty Ranks Non-federal Diabetes and Cancer

American Diabetes Association
2018 Core Research Program Grants Call for Applications

Researchers are trying to discover more about the complex relationships between diabetes and cancer.  There are risk factors shared between Diabetes and certain cancers.  Diabetes and cancer are considered to be inflammatory diseases and involve inflammation at a cellular level.
Due Dates: Apr. 12 (OSR) Ι Apr. 16 (Sponsor)
Contact: Office of Sponsored Research (x6804)
Link: Core Program
Research Awards

Innovative Basic Science (IBS)

Supports basic research with novel and innovative hypotheses in any area relevant to the etiology or pathophysiology of diabetes and its complications that holds significant promise for advancing prevention, cure or treatment of diabetes. Applications proposing high-risk projects with the potential for high-impact results are encouraged, as are studies that may not be sufficiently developed for traditional funding sources.
Amount & Project Period: $345,000 (TOTAL) - 3 years
Eligibility: All Faculty Ranks
 

Innovative Clinical or Translational Science (ICTS)

Support for research with novel and innovative hypotheses, performed in human subjects, or research approaches to accelerate the transition of scientific discoveries into clinical application. Studies must directly involve human subjects, human samples and/or data, and offer considerable promise for advancing the cure, prevention or treatment of diabetes. Applications proposing high-risk projects with the potential for high impact results are encouraged, a are studies that may not be sufficiently developed for traditional funding sources.
Amount & Project Period: $600,000 (TOTAL) - 3 years
Eligibility: All Faculty Ranks
Development Awards

Junior Faculty Development (JDF)

These awards support early investigators.
Amount & Project Period: $552,000 (TOTAL) - 4 years
Eligibility: Must be full-time independent faculty w/< 10 years of research experience since their terminal degree (Note tenure-track position not required);
Cannot have previous or current NIH support (R00, R01, U01 or equivalent).
May not hold concurrent awards of similar intent (NIH K awards, foundation or non-profit career development awards), however may have completed previous NIH K or other career development funding;
Must dedicate at least 75% effort to research activities.
Training Awards

Postdoctoral Fellowship (PDF)

 Provides support for high quality training in disciplines and topics relevant to diabetes, in an environment conducive to beginning a career in diabetes research.
Amount & Project Period: From $47,484-$55,581/yr. plus $5,000/yr. training and $5,000/yr. fringe benefit allowances - up to 3 years
Eligibility: Researchers (PhD, MD, PharmD, DO, DPM, or equiv.) w/confirmed postdoc position by award start date;
May not have more than 10 years research experience beyond conferral of doctoral degree;
Must be authorized to work in U.S. or U.S. possessions
 

Minority Postdoctoral Fellowship (PMF)

These fellowships are available to minority (African American or Black, Hispanic/Spanish/Latino, American Indian/Alaskan Native, and Native Hawaiian or Other Pacific Islander) postdoctoral researchers (MD, MD/PhD, PhD, DVM, or equiv.) who are underrepresented in biomedical research.
Amount & Project Period: From $47,484-$55,581/yr. plus $5,000/yr. training and $5,000/yr. fringe benefit allowances - up to 3 years
Eligibility: Researchers (PhD, MD, PharmD, DO, DPM, or equiv.) w/confirmed postdoc position by award start date;
May not have more than 10 years research experience beyond conferral of doctoral degree;
Must be authorized to work in U.S. or U.S. possessions
NEW
April 23, 3:00pm ET All Faculty Ranks Non-federal Prostate Cancer

Prostate Cancer Foundation
2018 PCF Challenge Awards for Metastatic, Lethal Prostate Cancer

The Request for Team Science Applications for PCF Challenge Awards is open.  Funding will be based on the level of innovation in applications received. Research proposals in the following topic areas are preferred:
1.  Immunotherapy for treatment of metastatic, lethal prostate cancer;
2.  Targeted radionuclide therapy for advanced prostate cancer;
3.  New systemic precision treatments for metastatic, lethal prostate cancer including those
     targeting the currently "undruggable";
4.  First-in-field research on new targets for systemic treatment of metastatic, lethal prostate
     cancer;
5.  Mechanisms of resistance to current and investigational drugs targeting the androgen 
     receptor and androgen axis, immune system, chemotherapy, and other targeted agents;
6.  Correlative research around either clinical trials of novel agents or strategies or standard
     of care;
7.  Developing or validating biomarkers that guide therapy in patients or further  
     understanding of mechanisms by which therapies work;
8.  Tumor microenvironment signaling related to cancer progression including the immune
     component;
9.  New bioinformatics technologies for analysis of genomic data and big data of clinical
     outcomes.
Due Dates: Apr. 19 (OSR) Ι Apr. 23 (Sponsor, 3:00pm ET)
Amount & Project Period: Up to $1M (Total) - 2 years
Eligibility: Team should be composed of at least 3 investigators capable of providing unique scientific expertise;
May be assembled from one institution, or several institutions; Must embed at least one young investigator as an integral contributor;
Young investigator may hold title of Postdoc, Instructor, Research Assoc., Asst. Professor, or equiv., and  be w/in 6 years of completing a professional degree (MD, DO, PhD, MD-PhD, DSc, ScD, DDM, DDS, DMD, MBBS, or equiv.) or subsequent mentored academic or clinical training program;
S/he must have been awarded no more than $200,000 in direct research funding from all sources including institutional funds during the 2-year term of this award.
Contact: Office of Sponsored Research (x6804)
Links: RFA Ι SmartSimple (Submission site) Ι PCF for Researchers
R01 NCI
 NEW
April 30 (LOI) All Ranks Federal Cancer Imaging

Perception and Cognition Research to Inform Cancer Image Interpretation (Clinical Trial Optional)

The purpose of this FOA is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.
Due Dates: Apr. 30 (Letter of Intent, not required or binding)
May 25 (OSR) Ι May 30 (Sponsor)
Additional Due Dates: Sept. 26th and May 30, & Sept. 26, 2019
Amount & Project Period: Application budgets not limited - 5 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-640
Companion FOA: PAR-18-641, R21

NEW
April 30 All Ranks Non-federal Research Projects

Elsa U. Pardee Foundation
Research Grants

The Foundation funds research directed toward identifying new treatments or cures for cancer, and particularly encourages applications allowing establishment of capabilities of new cancer researchers, or new cancer approaches by established cancer researchers.
Due Dates: Apr. 26 (OSR) Ι Apr. 30 (Sponsor)
Additional Annual Due Dates:  Aug. 31 and Jan. 31
Amount & Project Period: Funding amounts not specified - generally one year
Eligibility: All Ranks - new cancer researchers or new approaches by established cancer researchers
Contact: Office of Sponsored Research (x6804)
Link: Grant Application Process
U01 NCI
NEW
May 05 (LOI) All Ranks Federal "Traceback" testing

Traceback Testing: Increasing Identification and Genetic Counseling of Mutation Carriers through Family-based Outreach (Clinical Trial Optional)  

The purpose is to support pilot research projects using a "Traceback" approach to genetic testing women with a personal or family history of ovarian cancer and reaching out to family members to identify unaffected individuals at increased risk for cancer in different clinical contexts and communities, including racially/ethnically diverse populations.
Due Dates: May 05 (Letter of Intent, not required, or binding)
Applications Due: June 01 (OSR) Ι June 05 (Sponsor)
Additional Dates:  Standard dates
Amount & Project Period: Application budgets not limited - 4 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-616
R01 NIH
NCI is a participating Institute NEW
May 06 (LOI) All Ranks Federal Disparities

Surgical Disparities Research (Clinical Trial Optional)

The purpose is to support investigative and collaborative research focused on understanding and addressing disparities in surgical care and outcomes, in minority and health disparity populations. (See FOA for NCI topics of interest, Part II Section 1).
Due Dates: May 06 (Letter of Intent, not required or binding)
Applications Due: June 05 (OSR) Ι June 07 (Sponsor)
Additional Due Date:  June 7, 2019
Amount & Project Period: Budgets are not limited - 5 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-288
Companion FOA: PAR-18-289 R21 Clinical Trial Optional
U01 NIH
NCI is a participating Institute NEW
May 08 All Ranks Federal Biomedical

Bioengineering Research Partnerships (Clinical Trial Optional)

This FOA Invites applications to accelerate development and adoption of promising tools and technologies that can address important biomedical problems.  Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project.
Due Dates: May 04 (OSR) Ι May 08 (Sponsor)
Additional Due Date:  Sept. 13
Amount & Project Period: Application budgets are not limited - 5 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-208
Companion FOAs: PAR-18-206  R01 (Clinical Trial Optional)
PA-18-286    R21 (Clinical Trial Optional)
Due Dates:  Standard dates for companion FOAs
U01 NIH
NCI is a participating Institute NEW
May 09 (LOI) All Ranks Federal Aging and Cancer

Partnership for Aging and Cancer Research (Clinical Trial Not Allowed)  

This FOA is a joint effort between NCI and NIA to promote research that will advance current understanding of the mechanisms by which aging impacts cancer onset, progression, metastasis, and therapeutic response. To maximize collaborative interactions for this program, NIH extramural scientists will collaborate with investigators in the NCI Center for Cancer Research (NCI CCR) and/or the NIA Intramural Research Programs (NIA IRP) to address key questions on the aging contribution to cancer.
Due Dates: May 09 (Letter of Intent, not required or binding)
Applications Due:  June 06 (OSR) Ι June 08 (Sponsor)
Amount & Project Period: Not to exceed $75,000/yr. (Direct Costs) for extramural research component - 2 years
Eligibility: All Ranks - An investigator from NCI Center for Cancer Research must serve as co-investigator, and collaborators from NIA and other divisions in NCI intramural research program are also encouraged. Intramural collaborators should be tenured or tenure-track scientists and should have had previous contact with the PD(s)/PI(s) regarding the collaborative project proposed in the application.
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-552
R01 NIH
NCI is a participating Institute 
NEW
May 14 All Ranks Federal Native American Health

Intervention Research to Improve Native American Health (Clinical Trial Optional)

The purpose of this funding opportunity announcement (FOA) is to encourage research to improve Native American (NA) health.  NCI is interested in applications focusing on both individual and community interventions relating to primary and secondary cancer prevention and treatment. NCI is also interested in applications related to communication, attitudes, and knowledge of cancer risk factors (such as tobacco exposure, energy imbalance, and alcohol use).
Due Dates: Apr. 13 (Letter of Intent)
Applications Due: May 10 (OSR) Ι May 14(Sponsor)
Amount & Project Period: Budgets are not limited - 5 years
Eligibility: All Ranks
Contact: Budgets are not limited – 5 years
FOA Link: PAR-17-473
Companion FOA: PAR-17-464, R21
Toolbox
Funding Opportunities

Funding Opportunity Calendar
OSR's Grant News
grants.gov
NCI Funding Opportunities
NIH Guide to Grants & Contracts

RaceTracks

 Federal Opportunities
Moffitt-Sponsored (Intramural) Opportunities
Opportunities Focused on Thoracic Oncology		 Grant Preparation

Proposal Submission Form
Grants.gov Instructions
PHS398 Instructions
NIH 2590 Instructions

News

 NIH Research Matters
The Cancer Letter
NIH News & Events
Federal Register
Science 360 News
 Other

PubMed
National Cancer Institute

Clinical Research

Who To Call in Clinical Research
Clinical Research FAQs
Data Safety Monitoring Plan
Liberty IRB
USF IRB
Questions?
MRISignals@moffitt.org